This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Invasive fungal infections in solid organ transplant recipients
Invasive fungal infections and chronic obstructive pulmonary disease
Information on how to access prescribing information and adverse event reporting can be found towards the bottom of the page.
CRESEMBA® (isavuconazole) is indicated in adults for the treatment of invasive aspergillosis and mucormycosis in patients for whom amphotericin B is inappropriate.1
Choosing an appropriate antifungal drug can be difficult for a variety of reasons, and considerations may include:2-4
AEs and treatment discontinuations in the SECURE trial13 | |||
---|---|---|---|
CRESEMBA® (n=257) | Voriconazole (n=259) | p value | |
Any TEAE | 96% | 98% | 0.122 |
Drug-related TEAEs | 42% | 60% | <0.001 |
TEAEs leading to discontinuation | 14% | 23% | – |
Drug-related AEs leading to discontinuation | 8% | 14% | – |
Example
Drug-related AEs that were reduced with CRESEMBA® vs voriconazole13 | |||
---|---|---|---|
CRESEMBA® (n=257) |
Voriconazole (n=259) | p value | |
Skin and subcutaneous tissue disorders | 33% | 42% | 0.037 |
Eye disorders | 15% | 27% | 0.002 |
Hepatobiliary disorders | 9% | 16% | 0.016 |
In the VITAL trial, the AE profile of CRESEMBA® for the treatment of mucormycosis was consistent with observations from the SECURE trial. Only 16% (n=6/37) of patients with mucormycosis discontinued CRESEMBA® due to AEs14
Recommendations for the coadministration of CRESEMBA® with key medications4,c | ||
---|---|---|
Concomitant medication |
|
|
Recommendation | No dose adjustment for either CRESEMBA® or the concomitant medication | Monitoring of concomitant medication and dose adjustment if required |
Example
Please refer to the CRESEMBA® Summary of Product Characteristics for full list of drug interactions and recommendations concerning coadministration.
c. CRESEMBA® is contraindicated in coadministration with ketoconazole, high-dose ritonavir, and strong CYP3A4/5 inducers such as rifampicin, rifabutin, carbamazepine, long acting barbiturates, phenytoin and St. John’s wort, or with moderate CYP3A4/5 inducers such as efavirenz, nafcillin and etravirine.1 For further details and a full list of drug interactions, please consult the Summary of Product Characteristics.
Whether faced with invasive aspergillosis, or mucormycosis where amphotericin B is inappropriate, CRESEMBA® ensures that your patients are covered, and is also recommended by guidelines1,5-12
Click here for CRESEMBA® (isavuconazole) and Vfend (voriconazole) prescribing information
References:
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021